Akeso Biomedical: Funding, Investors & Team (Oct 2026)
Akeso Biomedical is an early-stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds. The Company is developing products to treat these conditions using a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of bacteria, and a silk biomaterial technology exclusively licensed from Tufts University. It was founded in 2014 and headquartered in Waltham, Massachusetts.
Akeso Biomedical has raised $600k across 1 funding round on record, the most recent an undisclosed round of $600k announced in Feb 2021.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Akeso Biomedical Company Profile and Key Stats
Latest funding round on record: Feb 2021.
Akeso Biomedical Funding Rounds
Akeso Biomedical Founders and Leadership Team
Contact details for the Akeso Biomedical team: 1 of 1 has an email address on file.
Start 14-day free trial →Akeso Biomedical Funding Compared to Other Biotechnology Startups
Akeso Biomedical's latest round of $600k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Akeso Biomedical in Biotechnology and Waltham
Companies Similar to Akeso Biomedical
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Akeso Biomedical Funding FAQs
What does Akeso Biomedical do?
Akeso Biomedical is an early-stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds. The Company is developing products to treat these conditions using a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of bacteria, and a silk biomaterial technology exclusively licensed from Tufts University. It was founded in 2014 and headquartered in Waltham, Massachusetts.
How much funding has Akeso Biomedical raised?
Akeso Biomedical has raised $600k across 1 round on record. The most recent is an undisclosed round of $600k announced in Feb 2021.
When did Akeso Biomedical last raise funding?
Akeso Biomedical's most recent funding round on record is an undisclosed round of $600k, announced in Feb 2021.
Who is the CEO of Akeso Biomedical?
Simon Williams is listed as CEO at Akeso Biomedical.
Where is Akeso Biomedical headquartered?
Akeso Biomedical is based in Waltham, Massachusetts, United States.
How many employees does Akeso Biomedical have?
Akeso Biomedical is in the 1-10 employee band.
How does Akeso Biomedical's funding compare to other Biotechnology startups?
Akeso Biomedical's latest round of $600k is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Akeso Biomedical Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Akeso Biomedical is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.